Zimmer Biomet Holdings (ZBH) : Traders are bullish on Zimmer Biomet Holdings (ZBH) as it has outperformed the S&P 500 by a wide margin of 1.02% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.15%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.32% in the last 1 week, and is up 0.48% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 2.46% and the 50-Day Moving Average is 1.72%.The 200 Day SMA reached 14.63%
Zimmer Biomet Holdings (NYSE:ZBH): After opening at $128.67, the stock dipped to an intraday low of $128.2515 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $130.49 and the buying power remained strong till the end. The stock closed at $130.02 for the day, a gain of 1.71% for the day session. The total traded volume was 1,391,322. The stocks close on the previous trading day was $130.02.
Zimmer Biomet Holdings (ZBH) : 16 Wall Street analysts covering Zimmer Biomet Holdings (ZBH) believe that the average level the stock could reach for the short term is $141.88. The maximum price target given is $155 and the minimum target for short term is around $120, hence the standard deviation is calculated at $10.01.
Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc. is a musculoskeletal healthcare company. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company manages its operations through three geographic segments: the Americas, comprising principally of the United States and includes other North, Central and South American markets; Europe, comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions, such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers, and directly to dental practices and dental laboratories.